Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer

Standard treatment for unresectable papillary thyroid carcinoma (PTC) is a multi-kinase inhibitor, including lenvatinib and sorafenib. Rearranged during transfection (RET) fusions are found in approximately 10% of PTC. Here, we present a case of metastatic RET fusion-positive PTC with long-term dise...

Descripción completa

Detalles Bibliográficos
Autor principal: Yokota, Tomoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941774/
https://www.ncbi.nlm.nih.gov/pubmed/36825106
http://dx.doi.org/10.1159/000526030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9941774/
https://www.ncbi.nlm.nih.gov/pubmed/36825106
http://dx.doi.org/10.1159/000526030

Ejemplares similares